Full-Time
Senior Data Scientist
Posted on 10/31/2025
Cardiosense
11-50 employees
Non-invasive cardiac monitoring with AI analytics
Compensation Overview
$108k - $165k/yr
Chicago, IL, USA
Hybrid
 Data & Analytics (1) |
|---|
- Master's or Ph.D. in Data Science, Computer Science, Statistics, Mathematics, or related field.
- 3+ years of professional experience in data science or machine learning roles.
- Demonstrated experience leading data science projects or teams.
- Expertise in programming languages such as Python, R, or Scala.
- Strong proficiency in machine learning frameworks (TensorFlow, PyTorch, Scikit-learn).
- Experience with big data tools (e.g., Spark, Hadoop) and cloud platforms (AWS, Azure, GCP).
- Strong analytical thinking and problem-solving abilities.
- Excellent communication and presentation skills.
- Proven ability to influence cross-functional teams and stakeholders.
- Data Strategy: Collaborate with cross-functional teams to identify opportunities for leveraging company data to drive business solutions.
- Collaborate with clinical teams and external vendors to facilitate data collection.
- Model Development & Deployment: Design, develop, and deploy scalable machine learning models and advanced analytics.
- Apply digital signal processing techniques to physiological waveforms (PPG, ECG, SCG, etc.) and build novel machine learning algorithms for hemodynamic assessment.
- Optimize existing algorithms and pipelines to improve efficiency and performance.
- Own the end-to-end lifecycle of models, from research and prototyping to production and monitoring.
- Advanced Analytics: Perform exploratory data analysis to extract actionable insights.
- Develop predictive, prescriptive, and descriptive analytics to inform decision-making.
- Work with structured and unstructured data to uncover trends and patterns.
- Data Infrastructure & Tools: Partner with data engineering teams to ensure the availability of robust data pipelines.
- Recommend and implement data tools, frameworks, and platforms to enhance workflows.
- Stakeholder Engagement: Communicate complex findings and recommendations to technical and non-technical stakeholders.
- Translate business objectives into data science tasks and projects.
- Industry experience in healthcare or medical device environment.
- Familiarity with MLOps and automated pipelines.
Cardiosense develops a non-invasive cardiac monitoring platform that uses wearable biometric sensors and artificial intelligence to analyze the full electromechanical behavior of each heartbeat. The system continuously tracks heart electrical signals and mechanical activity to provide early warnings of declining heart function. By selling the devices and offering a subscription-based analytics platform, Cardiosense targets hospitals and clinics to help healthcare teams prioritize at-risk patients and enable proactive interventions. Unlike traditional monitoring that relies on invasive methods or single-signal data, Cardiosense combines multiple data streams and AI-driven insights to detect signs of deterioration before symptoms appear. The company aims to improve patient outcomes by enabling timely care while the technology remains investigational under U.S. law.
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Simplify's Take
What believers are saying
- CMS expanded remote patient monitoring reimbursement codes in 2025 directly fund heart failure management platforms.
- Heart failure readmission costs exceed $40 billion annually, creating strong payer incentives for early detection.
- EHR integration becoming standard requirement positions Cardiosense for rapid Epic and Cerner health system deployment.
What critics are saying
- CardiosensAI competitor predicts cardiac events 24 hours in advance with real-time AI, eroding first-mover advantage.
- FDA approval delays beyond investigational use block CardioTag commercialization and analytics subscription revenue streams.
- Burn rate exhaustion post-$15.1M Series A with no Series B evident forces dilution or shutdown.
What makes Cardiosense unique
- Multi-modal sensor fusion (ECG, SCG, PPG) achieves 92% accuracy correlating with invasive hemodynamic measurements.
- FDA Breakthrough Device designation for early heart failure detection algorithm enables expedited regulatory pathway.
- Physiological waveform AI platform generates actionable decompensation risk biomarkers, not passive data collection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 2%Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page